Skip to main content

Table 3 Demographic data of patients taking predominant sodium channel blocking antiseizure medications

From: Response to Sodium Channel blocking Antiseizure medications and coding polymorphisms of Sodium Channel genes in Taiwanese epilepsy patients

  All (n = 82) Response (n = 58) Not seizure-free (n = 24) p
Onset age (year) 17.5 (12.8–26.0) 15.0 (8.0–19.0) 19.0 (15.0–28.0) 0.020
Male 34 (41.5) 24 (41.4) 10 (41.7) reference
Female 48 (58.5) 34 (58.6) 14 (58.3) 0.981
Seizure type
 Focal 51 (62.2) 34 (58.6) 17 (70.8) 0.382
 Generalized 17 (20.7) 12 (20.7) 5 (20.8)  
 Unspecified 14 (17.1) 12 (20.7) 2 (8.3)  
Etiology
 Structural 13 (15.9) 8 (13.8) 5 (20.8) 0.072
 CNS infection 4 (4.9) 3 (5.2) 1 (4.2)  
 Genetic 1 (1.2) 0 (0.0) 1 (4.2)  
 Autoimmune 2 (2.4) 0 (0.0) 2 (8.3)  
 Unknown 62 (75.6) 47 (81.0) 15 (62.5)  
Number of ASMs
 1 46 (56.1) 40 (69.0) 6 (25.0)  
 2 23 (28.0) 13 (22.4) 10 (41.7)  
 3 12 (14.6) 5 (8.6) 7 (29.2)  
 4 0 (0.0) 0 (0.0) 0 (0.0)  
 5 1 (1.2) 0 (0.0) 1 (4.2)  
Concurrent ASMs
 Carbamazepine 29 21 8  
 Clobazam 3 2 1  
 Gabapentin 1 0 1  
 Lacosamide 2 0 2  
 Lamotrigine 34 24 10  
 Levetiracetam 24 10 14  
 Oxcarbazepine 10 6 4  
 Perampanel 1 0 1  
 Phenobarbital 1 0 1  
 Phenytoin 27 18 9  
 Vigabatrin 1 0 1  
  1. Continuous variables were presented as median (interquartile range)
  2. Categorical variables were presented as n (%)
  3. Abbreviations: CNS central nervous system, ASM antiseizure medication